Cold Agglutinin Disease Treatment Market By Therapy Class (Complement Inhibitors, B-Cell-Directed Therapies, Immunosuppressants, and Other Emerging Treatments); by Route of Administration (Intravenous, Oral, and Subcutaneous); by Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, and Retail Pharmacies); and by Geography, Segment Revenue Estimation, Forecast, 2026–2032

Cold Agglutinin Disease Treatment Market: Enjaymo Revenue, Durable B-Cell Therapy, and Oral Pipeline Programs Reshape Competition

The Global Cold Agglutinin Disease Treatment Market was valued at USD 148.96 million in 2025 and is expected to reach USD 343.56 million by 2032 at a 12.68% CAGR, as reported by Strategic Market Research.

 

The Cold Agglutinin Disease Treatment Market has moved from a largely off-label treatment category into a defined rare-disease commercial segment. This shift followed the approval of Enjaymo, or sutimlimab, the first therapy developed specifically to reduce red blood cell destruction in adults with cold agglutinin disease. The U.S. Food and Drug Administration approved Enjaymo in February 2022, followed by approvals in the European Union and Japan during the same year.

 

Cold agglutinin disease, or CAD, is a rare autoimmune hemolytic anemia that causes premature destruction of red blood cells. Despite the small diagnosed population, repeated monitoring, specialist care, transfusions, infusions, and long-term management make it commercially significant relative to its prevalence.

 

Recent U.S. claims research estimated CAD incidence at approximately 0.6 to 1.2 cases per 100,000 people and annual prevalence at 1.4 to 3.1 cases per 100,000. Prevalence rises with age and is higher among women. A multinational study also found a climate effect, reporting approximately 20 cases per million people in colder regions compared with five per million in warmer areas. Recordati estimates that around 11,000 diagnosed patients live across the United States, Europe, and Japan, indicating the potential addressable population for targeted treatment, although this is a company estimate.

 

A Small Patient Population Creates a High Healthcare Burden

Treatment demand reflects the clinical burden of uncontrolled anemia and hemolysis. Patients may experience severe fatigue, dyspnea, weakness, jaundice, cold-induced circulatory symptoms, and recurrent transfusion requirements. In a multinational study of 232 patients, mean baseline hemoglobin was 9.3 g/dL, and 27% had levels below 8 g/dL, confirming a substantial subgroup with severe anemia.

Healthcare-resource data show how this burden converts into treatment demand. A Danish study comparing 104 CAD patients with 1,003 matched individuals found that 53% of CAD patients required inpatient hospitalization after diagnosis, compared with 23% of controls. Average inpatient stays were 10.6 days for patients with CAD and 2.7 days for matched individuals. Blood transfusions were recorded for 43% of CAD patients but only 1% of controls.

CAD also carries complications beyond anemia. A Japanese claims analysis involving 344 patients with CAD and 3,440 matched controls found thromboembolic events in 34.9% of CAD patients, compared with 17.9% of controls. Patients with CAD had 2.81 times higher odds of experiencing thromboembolism. This burden gives payers a reason to evaluate therapies not only by acquisition cost but also by their ability to reduce transfusion, hospitalization, and acute disease management.

 

Complement Inhibition Created the First Dedicated CAD Drug Segment

Before Enjaymo, treatment relied mainly on therapies borrowed from other hematological conditions. Rituximab, bendamustine, transfusion support, and cold-avoidance measures remain important, but none was originally approved specifically for CAD. Enjaymo created a separate complement-inhibitor segment by blocking the immune pathway responsible for rapid red blood cell destruction.

Sutimlimab targets C1s, an upstream component of the classical complement pathway. Its commercial advantage is speed. It can control hemolysis and raise hemoglobin without waiting for the antibody-producing B-cell population to decline. This is valuable when severe anemia or transfusion dependence requires rapid control.

In the pivotal CARDINAL study, 54% of patients met the composite response endpoint. Approximately 71% remained free from transfusion after week five during the initial treatment period. Longer follow-up showed mean hemoglobin above 11 g/dL from week five through week 53, while the proportion remaining transfusion-free increased from 70.8% during weeks five to 26 to 86.4% during weeks 27 to 53.

The randomized CADENZA study extended the evidence to patients who had not recently required transfusion. Seventy-three percent of patients receiving sutimlimab met the composite endpoint, compared with 15% receiving placebo. These results supported use beyond the most transfusion-dependent population.

The treatment has commercial limitations. Enjaymo is administered intravenously every two weeks, requires vaccination against certain encapsulated bacteria, and usually must be continued to maintain hemolysis control. Disease activity may return after discontinuation because complement inhibition does not eliminate the B-cell clone producing cold agglutinins. It also does not directly resolve cold-induced circulatory symptoms. These limitations support recurring revenue while creating demand for more convenient or disease-modifying alternatives.

 

B-Cell-Directed Therapy Retains a Strong Market Position

Rituximab-based treatment remains established because it acts on the source of pathogenic antibody production rather than only blocking the resulting hemolysis. Rituximab monotherapy produces a response in about half of treated patients, although complete responses are uncommon and median response duration generally ranges from 6.5 to 11 months. Physician familiarity, lower costs, and biosimilars preserve its relevance where Enjaymo access is limited. durability

Combining rituximab with bendamustine offers greater for medically fit patients with substantial disease burden. In a multinational observational analysis, the combination produced an overall response rate of 78%, including complete responses in 53% of patients. Among responders, the estimated rate of sustained remission at five years was 77%.

The combination’s durability creates a clear difference from Enjaymo. Sutimlimab offers rapid control but generally requires continuous infusion, while rituximab plus bendamustine can produce a treatment-free remission after a limited course. The trade-off is slower response and greater short-term toxicity, making intensive B-cell-directed treatment less suitable for older, frail, or acutely anemic patients.

Differences in study populations and endpoints make treatment selection dependent on the clinical priority, including rapid hemolysis control, transfusion avoidance, durable remission, or lower chemotherapy exposure.

Older therapies now have a limited role. Corticosteroids usually produce weak and short-lived responses in CAD, while splenectomy offers little benefit because red blood cell clearance occurs mainly in the liver. Eculizumab can reduce intravascular hemolysis and transfusion requirements, but its effect on hemoglobin is modest and it does not relieve cold-induced circulatory symptoms.

 

Enjaymo Revenue Confirms the Market’s Commercial Potential

The clearest evidence of market value comes from Enjaymo revenue rather than unsupported top-down estimates. Recordati reported worldwide Enjaymo sales of €146.3 million in 2025. The result shows that a rare disease affecting only several thousand diagnosed patients can support meaningful product revenue when treatment is targeted, chronic, and priced as an orphan therapy.

Commercial momentum continued in 2026. Recordati reported first-quarter Enjaymo revenue of €43.9 million, representing growth of 37.6% from the comparable period. The company attributed performance to continued uptake across major geographies.

Recordati acquired global rights to Enjaymo from Sanofi in a transaction completed in November 2024. The agreement included an upfront payment of USD 825 million and potential commercial milestone payments of up to USD 250 million. Recordati initially projected annual peak sales of approximately €250 million to €300 million, indicating expectations of further patient identification, geographic expansion, and deeper treatment penetration.

The acquisition reflects the appeal of established rare-disease biologics with orphan protections, concentrated specialist prescribing, limited direct competition, and recurring revenue. Enjaymo’s position will still depend on reimbursement and future therapies offering greater convenience or durability.

 

The United States Leads Commercial Adoption

The United States benefited from first-market approval, specialist infusion infrastructure, orphan-drug reimbursement, and a dedicated HCPCS billing code for sutimlimab. These factors reduced administrative uncertainty and supported earlier uptake.

Recordati reported that the United States accounted for approximately 56% of Enjaymo sales during the 12 months ending August 2024. Japan represented around 30%, while Europe accounted for about 14%. Although these are historical company figures rather than a current geographic split, they show that the United States and Japan commercialized targeted CAD treatment faster than Europe.

Japan remains important because of its rare-disease treatment infrastructure and early approval, which allowed Enjaymo to build revenue before broader European reimbursement.

 

European Access Remains Uneven

European regulatory approval has not produced uniform access. National health-technology assessments have reached different conclusions on eligible patients and comparative value.

France supported reimbursement for adults with CAD whose hemoglobin level is 10 g/dL or lower but did not support reimbursement above that threshold. The agency recognized clinical benefit in more severely anemic patients while noting the absence of benefit for cold-induced vascular symptoms and the burden of treatment every two weeks.

Germany’s Federal Joint Committee found a hint of minor additional benefit, mainly through improvement in fatigue, but identified no relevant difference in mortality, broad quality-of-life measures, or adverse events. In the United Kingdom, the NICE appraisal remained awaiting development as of November 2025. These differences show that European market growth depends as much on reimbursement and evidence of value as on regulatory authorization.

Manufacturers must identify patients likely to gain sufficient benefit to justify chronic treatment costs while lower-cost rituximab-based regimens remain available.

 

Hospital Infusion Settings Dominate Current Delivery

Intravenous therapy remains the dominant route of administration. Enjaymo requires repeat infusions, while rituximab and bendamustine are also administered in specialist settings. Hospitals, hematology centers, and infusion clinics therefore manage most treatment activity.

This concentrated prescriber base simplifies commercial targeting but limits adoption where infusion capacity, vaccination requirements, monitoring, reimbursement, and repeated visits create access barriers.

An approved oral complement inhibitor could shift part of CAD treatment away from infusion centers and reduce travel and chair-time burdens. No oral targeted therapy is currently approved, making administration convenience a meaningful pipeline differentiator.

 

The Pipeline Is Selective Rather Than Crowded

The CAD pipeline is active but remains relatively early-stage. Several programs have shown scientific activity, but few are positioned to challenge Enjaymo in the near term.

Annexon is evaluating ANX1502, an oral inhibitor of the classical complement pathway, in a proof-of-concept study involving patients with CAD. A clinical update is expected during 2026. Sustained oral complement suppression would directly address one of Enjaymo’s main disadvantages.

Riliprubart, formerly SAR445088, showed complement inhibition and preliminary activity in a small Phase 1b study involving 12 adults. Sanofi decided in July 2024 not to advance the program into Phase 3 for CAD, citing portfolio prioritization. The decision shows the commercial difficulty of developing another therapy for a small population already served by a drug targeting the same pathway.

Plasma-cell-directed approaches are another emerging area. Bortezomib produced an overall response rate of approximately 31.6% in a Phase II study, while small retrospective reports involving daratumumab have shown hemoglobin improvement in some heavily treated patients. These findings remain limited by small patient numbers and are not sufficient to establish a broad standard of care.

Near-term pipeline opportunity is concentrated in oral complement inhibition, therapies capable of producing durable remission without chemotherapy, and combinations that use rapid complement control while slower B-cell- or plasma-cell-directed treatment begins to work.

 

Competition Will Depend on the Treatment Objective

The Cold Agglutinin Disease Treatment Market does not have one treatment pathway suitable for every patient. Enjaymo is positioned strongly where rapid correction of hemolysis and transfusion avoidance are priorities. Rituximab monotherapy remains relevant for patients seeking a limited treatment course or where reimbursement restricts targeted therapy. Rituximab plus bendamustine is differentiated by durable remission but is generally reserved for patients able to tolerate more intensive treatment.

This division prevents Enjaymo from becoming the only CAD therapy while protecting it from complete displacement by lower-cost alternatives. Its strongest commercial position is among patients with symptomatic anemia, recurrent hemolysis, transfusion requirements, inadequate responses to B-cell treatment, or contraindications to chemotherapy.

Competitive pressure may initially come from treatment sequencing rather than another approved drug. Physicians may use sutimlimab to control active hemolysis and later introduce clone-directed therapy intended to achieve treatment-free remission. This approach could reduce treatment duration per patient even as the number of patients exposed to Enjaymo increases.

 

Diagnosis and Real-World Evidence Will Shape Market Growth

Improved diagnosis is one of the largest remaining sources of market expansion. U.S. claims estimates vary across databases, while climate, age, referral practices, coding, and testing influence reported prevalence. Patients with fatigue or anemia may remain undiagnosed until symptoms become severe or transfusions are required. More consistent testing and referral to hematologists could expand the treated population without any increase in underlying incidence.

Real-world evidence will also influence reimbursement. Payers will examine whether Enjaymo reduces transfusions, hospitalization, emergency care, and daily activity impairment outside controlled trials. This evidence is particularly important because clinical benefit must be weighed against chronic infusion costs and the availability of less expensive off-label treatment.

Market growth will therefore come from deeper penetration of the diagnosed population, earlier identification of symptomatic patients, additional European reimbursement decisions, continued uptake in Japan, and evidence supporting treatment before repeated transfusion dependence develops. Enjaymo’s €146.3 million in 2025 sales confirms that targeted CAD treatment has established a meaningful orphan-drug franchise. Future competition will depend less on another intravenous complement antibody and more on improved convenience, shorter treatment duration, control of cold-induced symptoms, and durable remission without chemotherapy.

 

Cold Agglutinin Disease Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 148.96 Million
Revenue Forecast in 2032	USD 343.56 Million
Overall Growth Rate	CAGR of 12.68% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Therapy Class, By Route of Administration, By Distribution Channel, By Geography
By Therapy Class	Complement Inhibitors, B-Cell-Directed Therapies, Immunosuppressants, Other Emerging Treatments
By Route of Administration	Intravenous, Oral, Subcutaneous
By Distribution Channel	Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising diagnosis of rare autoimmune hemolytic anemia, increasing adoption of targeted complement therapies, growing demand for transfusion-reducing treatments, expansion of specialty hematology care, advancement of oral and durable B-cell-directed pipeline programs
Customization Option	Available upon request